BidaskClub Upgrades AngioDynamics (NASDAQ:ANGO) to Buy

AngioDynamics (NASDAQ:ANGO) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Friday, BidAskClub reports.

Several other analysts have also commented on ANGO. Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, June 4th. TheStreet lowered shares of WCF Bancorp from a “c” rating to a “d+” rating in a research note on Thursday, April 18th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. AngioDynamics presently has an average rating of “Buy” and an average target price of $21.50.

Shares of NASDAQ:ANGO opened at $21.68 on Friday. The stock has a 50 day moving average of $19.62. The firm has a market cap of $814.66 million, a price-to-earnings ratio of 26.12 and a beta of 0.69. AngioDynamics has a twelve month low of $18.11 and a twelve month high of $25.48. The company has a current ratio of 4.30, a quick ratio of 1.70 and a debt-to-equity ratio of 0.20.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The company had revenue of $96.30 million during the quarter, compared to analyst estimates of $92.34 million. During the same period in the prior year, the company posted $0.20 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. Equities analysts forecast that AngioDynamics will post 0.27 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in AngioDynamics by 2.8% during the fourth quarter. BlackRock Inc. now owns 5,918,221 shares of the medical instruments supplier’s stock valued at $119,134,000 after purchasing an additional 158,932 shares during the last quarter. Victory Capital Management Inc. lifted its stake in AngioDynamics by 38.3% during the first quarter. Victory Capital Management Inc. now owns 2,686,696 shares of the medical instruments supplier’s stock valued at $61,418,000 after purchasing an additional 744,085 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of AngioDynamics by 19.2% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,136,657 shares of the medical instruments supplier’s stock valued at $22,881,000 after acquiring an additional 183,368 shares in the last quarter. Tributary Capital Management LLC lifted its position in shares of AngioDynamics by 39.9% in the 1st quarter. Tributary Capital Management LLC now owns 704,499 shares of the medical instruments supplier’s stock valued at $16,105,000 after acquiring an additional 200,829 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of AngioDynamics by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 664,744 shares of the medical instruments supplier’s stock valued at $13,381,000 after acquiring an additional 14,997 shares in the last quarter. 98.46% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Article: Technical Analysis of Stocks and What It Means

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit